6.30
  Price0.56%   +0.0350
(After Hours: 6.27 -0.0250 -0.40%)
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.
Cap:    |  Volume (24h):